IKZF2 Degradation: It's Time to Take into Account it When Designing Cereblon-Based PROTACs

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Drug Discovery

Background:

• Proteolysis-targeting chimeras (PROTACs) are an emerging therapeutic modality for protein degradation.
• PROTACs utilizing the E3 ligase cereblon (CRBN) dominate clinical research, accounting for over 90% of candidates.
• CRBN ligands, acting as molecular glues, can degrade neo-substrate proteins, a mechanism less explored than direct target degradation.

Purpose of the Study:

• To comprehensively review published IKZF2 degraders from scientific literature and patents.
• To highlight the significance of IKZF2 degradation within the context of CRBN-based PROTAC development.
• To provide insights for medicinal chemists designing PROTACs for targeted IKZF2 degradation.

Main Methods:

• Systematic literature search for IKZF2 degraders.
• Patent landscape analysis of IKZF2-targeting molecules.
• Medicinal chemistry perspective on structure-activity relationships of IKZF2 degraders.

Main Results:

• Identification and compilation of various IKZF2 degraders reported in published articles and patents.
• Analysis of the chemical space and design strategies employed for IKZF2 degradation.
• Emphasis on the potential of CRBN ligands to degrade neo-substrates like IKZF2.

Conclusions:

• IKZF2 degradation is an underappreciated area in PROTAC research.
• Existing IKZF2 degraders provide a foundation for designing novel CRBN-based PROTACs.
• Further research into IKZF2 degraders will advance PROTAC-mediated protein degradation therapies.